LON:SBTXSkinbiotherapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Skinbiotherapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 17.25 +0.08 (+0.47 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range 17Now: GBX 17.25▼ 17.4050-Day Range 7MA: GBX 14.08▼ 18.9052-Week Range 5Now: GBX 17.25▼ 26Volume244,944 shsAverage Volume261,826 shsMarket Capitalization£22.09 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd. SkinBioTherapeutics plc was founded in 2016 and is based in Macclesfield, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Skinbiotherapeutics. Previous Next 2.2 Community Rank Outperform VotesSkinbiotherapeutics has received 47 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSkinbiotherapeutics has received 62 “underperform” votes. (Add your “underperform” vote.)Community SentimentSkinbiotherapeutics has received 56.88% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Skinbiotherapeutics and other stocks. Vote “Outperform” if you believe SBTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSkinbiotherapeutics does not currently pay a dividend.Dividend GrowthSkinbiotherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Skinbiotherapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Skinbiotherapeutics is -15.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skinbiotherapeutics is -15.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSkinbiotherapeutics has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SBTX Previous Symbol CUSIPN/A CIKN/A Webwww.skinbiotherapeutics.com Phone+44-161-4682760Debt Debt-to-Equity RatioN/A Current Ratio15.76 Quick Ratio15.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.96 per share Price / Cash Flow8.82 Book ValueGBX 2.40 per share Price / Book7.19Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees6 Outstanding Shares128,083,000Market Cap£22.09 million Next Earnings DateN/A OptionableNot Optionable LSE:SBTX Rates by TradingView Receive SBTX News and Ratings via Email Sign-up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions How has Skinbiotherapeutics' stock been impacted by COVID-19 (Coronavirus)? Skinbiotherapeutics' stock was trading at GBX 8.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBTX shares have increased by 102.9% and is now trading at GBX 17.25. View which stocks have been most impacted by Coronavirus. How were Skinbiotherapeutics' earnings last quarter? Skinbiotherapeutics PLC (LON:SBTX) announced its earnings results on Tuesday, March, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter. View Skinbiotherapeutics' earnings history. Has Skinbiotherapeutics been receiving favorable news coverage? Media coverage about SBTX stock has trended very negative on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Skinbiotherapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSkinbiotherapeutics. Who are some of Skinbiotherapeutics' key competitors? Some companies that are related to Skinbiotherapeutics include Omega Diagnostics Group (ORPH), Novoheart (NVH), Immunoprecise Antibodies (IPA), Ampio Pharmaceuticals (AMPE), Acasti Pharma (ACST), Biopharmx (BPMX), AquaBounty Technologies (AQB), Orthocell (OCC), Synairgen (SNG), Cynata Therapeutics (CYP), Oxford Biodynamics (OBD), Pediapharm (PDP), Biotron (BIT), 4d Pharma (DDDD) and Actinium Pharmaceuticals (ATNM). View all competitors. What other stocks do shareholders of Skinbiotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Skinbiotherapeutics investors own include Anglo Pacific Group (APF), Avacta Group (AVCT), Inspired Energy (INSE), OptiBiotix Health (OPTI), LB-Shell (LBP), Namibian Resources (AAOG), Big Sofa Technologies Group (BST), Concepta (CPT), Fresnillo (FRES) and Shield Therapeutics (STX). Who are Skinbiotherapeutics' key executives? Skinbiotherapeutics' management team includes the following people: Dr. Catherine O'Neill, CEO, Chief Scientific Officer & DirectorMr. Douglas John Quinn, CFO, Company Sec. & DirectorMr. Stuart John Ashman, Exec. Director (Age 52) What is Skinbiotherapeutics' stock symbol? Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX." How do I buy shares of Skinbiotherapeutics? Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Skinbiotherapeutics' stock price today? One share of SBTX stock can currently be purchased for approximately GBX 17.25. How big of a company is Skinbiotherapeutics? Skinbiotherapeutics has a market capitalization of £22.09 million. Skinbiotherapeutics employs 6 workers across the globe. What is Skinbiotherapeutics' official website? The official website for Skinbiotherapeutics is www.skinbiotherapeutics.com. How can I contact Skinbiotherapeutics? Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760. This page was last updated on 5/28/2020 by MarketBeat.com Staff
